Gastrointestinal Cancer Risk in Steatotic Liver Diseases: <scp>MASLD</scp> , <scp>MetALD</scp> and <scp>ALD</scp>
Patients with SLD, including MASLD, MetALD and ALD, have a significantly higher risk of gastrointestinal cancers compared to the controls. The degree of risk varies according to the underlying liver disease subtype, particularly in relation to alcohol consumption. These findings underscore the importance of implementing risk-stratified cancer screening strategies in patients with SLD.
Authors
- Masayuki Kurosaki
- Shun‐ichi Wakabayashi (ORCID: https://orcid.org/0000-0002-4657-4785)
- Nobuharu Tamaki (ORCID: https://orcid.org/0000-0003-4634-6616)
- Naoki Tanaka (ORCID: https://orcid.org/0000-0002-3212-3836)
- Rohit Seth Loomba (ORCID: https://orcid.org/0000-0002-4845-9991)
- Namiki Izumi (ORCID: https://orcid.org/0000-0002-0055-8229)
- Takefumi Kimura (ORCID: https://orcid.org/0000-0002-1481-1029)
Institutions
- Shinshu University (JP)
- Musashino Red Cross Hospital (JP)
Publication Details
- Journal
- Alimentary Pharmacology & Therapeutics
- Published
- 2025-11-15
- DOI
- https://doi.org/10.1111/apt.70466
- Citations
- 4
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 5.42